The Binding Site Inc. has announced an expansion to its broad offering of clinical and research products and services to now include the Histone antigen manufactured by Arotec Diagnostics. Autoantibodies against Histones (AHA’s) are observed in a number of autoimmune diseases, especially with patients suffering from active Systemic Lupus Erythematosus (SLE).
AHA’s also have particular clinical significance for drug-induced lupus, particularly in the diagnosis of antinuclear antibody positive patients receiving procanamide, hydralazine and isoniazide. AHA’s are also seen in Felty’s syndrome, rheumatoid arthritis (RA), juvenile arthritis, scleroderma, systemic sclerosis and mixed connective tissue disease. In addition, AHA’s have also been observed in approximately 76% of patients with primary biliary cirrhosis.
Derived and sourced from bovine thymus of New Zealand origin, this Histone antigen exhibits exceptional degrees of activity and specificity, exceptional lot-to-lot consistency and shelf life stability, while demonstrating a product purity level in excess of 90%, as assessed by SDS gel electrophoresis. Expressly designed for use as a critical component in solid phase ELISA-based immunoassay test procedures, medical laboratory professionals, clinical researchers and manufacturers in-vitro diagnostic (IVD) of immunoassay kits and diagnostic tests for auto-immune conditions will certainly benefit from the availability of this product. Available in three separate operator-oriented packaging fill formats of 1.0 mg, 0.5 mg and 0.2 mg, customer distinct and bulk packaging configurations are also available.
The Binding Site, Inc. serves the in-vitro diagnostic and life science markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 5889 Oberlin Drive – Suite 101, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.thebindingsite.com.